Evaluating the effect of immune cells on the outcome of patients with mesothelioma

被引:48
作者
Chee, Serena J. [1 ,2 ]
Lopez, Maria [1 ,3 ]
Mellows, Toby [3 ,4 ]
Gankande, Sharmali [3 ]
Moutasim, Karwan A. [1 ,3 ]
Harris, Scott [5 ]
Clarke, James [1 ]
Vijayanand, Pandurangan [4 ]
Thomas, Gareth J. [1 ,6 ]
Ottensmeier, Christian H. [1 ,2 ,6 ]
机构
[1] Univ Southampton, Canc Sci Unit, Fac Med, Tremona Rd, Southampton SO16 6YD, Hants, England
[2] Southampton Gen Hosp, NIHR Southampton Biomed Res Ctr, Tremona Rd, Southampton SO16 6YD, Hants, England
[3] Univ Hosp Southampton NHS Fdn Trust, Dept Cellular Pathol, Tremona Rd, Southampton SO16 6YD, Hants, England
[4] Univ Southampton, Fac Med, Clin & Expt Sci, Southampton Natl Inst Hlth Res Resp,Biomed Res Un, Southampton SO16 6YD, Hants, England
[5] Univ Southampton, Publ Hlth Sci & Med Stat, Tremona Rd, Southampton SO16 6YD, Hants, England
[6] NIHR CRUK Expt Canc Med Ctr Southampton, Tremona Rd, Southampton SO16 7YD, Hants, England
关键词
mesothelioma; cancer immunology; tissue microarray; MALIGNANT PLEURAL MESOTHELIOMA; TUMOR-INFILTRATING LYMPHOCYTES; PROGNOSTIC VALUE; T-CELLS; OPEN-LABEL; CANCER; CHEMOTHERAPY; EXPRESSION; MUTATIONS; LANDSCAPE;
D O I
10.1038/bjc.2017.269
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: We systematically assessed the prognostic and predictive value of infiltrating adaptive and innate immune cells in a large cohort of patients with advanced mesothelioma. Methods: A tissue microarray from 302 samples was constructed. Markers of adaptive immune response in T-cells (CD8(+), FOXP3(+), CD4(+), CD45RO(+), CD3(+)) and B-cells (CD20(+)), and of innate immune response; neutrophils (NP57(+)), natural killer cells (CD56(+)) and macrophages (CD68(+)) were evaluated. Results: We found that in the epithelioid tumours, high CD4(+) and CD20(+) counts, and low FOXP3(+), CD68(+) and NP57(+) counts linked to better outcome. In the non-epithelioid group low CD8(+) and low FOXP3(+)counts were beneficial. On multivariate analysis low FOXP3(+) remained independently associated with survival in both groups. In the epithelioid group additionally high CD4(+), high CD20(+), and low NP57(+) counts were prognostic. Conclusions: Our data demonstrate for the first time, in predominately advanced disease, the association of key markers of adaptive and innate immunity with survival and the differential effect of histology. A better understanding of the immunological drivers of the different subtypes of mesothelioma will assist prognostication and disease-specific clinical decision-making.
引用
收藏
页码:1341 / 1348
页数:8
相关论文
共 41 条
  • [1] Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer
    Al-Shibli, Khalid I.
    Donnem, Tom
    Al-Saad, Samer
    Persson, Magnus
    Bremnes, Roy M.
    Busund, Lill-Tove
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (16) : 5220 - 5227
  • [2] Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
    Alley, Evan W.
    Lopez, Juanita
    Santoro, Armando
    Morosky, Anne
    Saraf, Sanatan
    Piperdi, Bilal
    van Brummelen, Emilie
    [J]. LANCET ONCOLOGY, 2017, 18 (05) : 623 - 630
  • [3] Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma
    Anraku, Masaki
    Cunningham, Kristopher S.
    Yun, Zhihong
    Tsao, Ming-Sound
    Zhang, Li
    Keshavjee, Shaf
    Johnston, Michael R.
    de Perrot, Marc
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2008, 135 (04) : 823 - 829
  • [4] Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
    Awad, Mark M.
    Jones, Robert E.
    Liu, Hongye
    Lizotte, Patrick H.
    Ivanova, Elena V.
    Kulkarni, Meghana
    Herter-Sprie, Grit S.
    Liao, Xiaoyun
    Santos, Abigail A.
    Bittinger, Mark A.
    Keogh, Lauren
    Koyama, Shohei
    Almonte, Christina
    English, Jessie M.
    Barlow, Julianne
    Richards, William G.
    Barbie, David A.
    Bass, Adam J.
    Rodig, Scott J.
    Hodi, F. Stephen
    Wucherpfennig, Kai W.
    Janne, Pasi A.
    Sholl, Lynette M.
    Hammerman, Peter S.
    Wong, Kwok-Kin
    Bueno, Raphael
    [J]. CANCER IMMUNOLOGY RESEARCH, 2016, 4 (12) : 1038 - 1048
  • [5] Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers
    Badoual, C
    Hans, S
    Rodriguez, J
    Peyrard, S
    Klein, C
    Agueznay, NE
    Mosseri, V
    Laccourreye, O
    Bruneval, P
    Fridman, WH
    Brasnu, DF
    Tartour, E
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (02) : 465 - 472
  • [6] Identification of IFN-γ-producing innate B cells
    Bao, Yan
    Liu, Xingguang
    Han, Chaofeng
    Xu, Sheng
    Xie, Bin
    Zhang, Qian
    Gu, Yan
    Hou, Jin
    Qian, Li
    Qian, Cheng
    Han, Huanxing
    Cao, Xuetao
    [J]. CELL RESEARCH, 2014, 24 (02) : 161 - 176
  • [7] The double life of a B-1 cell: self-reactivity selects for protective effector functions
    Baumgarth, Nicole
    [J]. NATURE REVIEWS IMMUNOLOGY, 2011, 11 (01) : 34 - 46
  • [8] Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
    Bindea, Gabriela
    Mlecnik, Bernhard
    Tosolini, Marie
    Kirilovsky, Amos
    Waldner, Maximilian
    Obenauf, Anna C.
    Angell, Helen
    Fredriksen, Tessa
    Lafontaine, Lucie
    Berger, Anne
    Bruneval, Patrick
    Fridman, Wolf Herman
    Becker, Christoph
    Pages, Franck
    Speicher, Michael R.
    Trajanoski, Zlatko
    Galon, Jerome
    [J]. IMMUNITY, 2013, 39 (04) : 782 - 795
  • [9] Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma
    Bograd, Adam J.
    Suzuki, Kei
    Vertes, Eva
    Colovos, Christos
    Morales, Eduardo A.
    Sadelain, Michel
    Adusumilli, Prasad S.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (11) : 1509 - 1527
  • [10] Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
    Brown, Jason R.
    Wimberly, Hallie
    Lannin, Donald R.
    Nixon, Christian
    Rimm, David L.
    Bossuyt, Veerle
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (23) : 5995 - 6005